Physicians' Academy for Cardiovascular Education

Low-risk profile in pulmonary arterial hypertension patients predicts better survival

June 6, 2017 - Kylhammar D, et al. - Eur Heart J 2017

Using the risk assessment instrument proposed by the ESC/ERS guidelines revealed better survival for pulmonary arterial hypertension (PAH) patients who remain at or achieve a low-risk profile in SPAHR trial, and supports goal-oriented treatment.

What is the underlying pathophysiology of PAH and what are its characteristics?

Pulmonary Arterial Hypertension (PAH) - video 1

Jan. 11, 2017 - Bologna, Italy - Nazzareno Galiè, MD
Series of videos in which Prof. dr. Galiè discusses the pathophysiology and management of pulmonary arterial hypertension (PAH), including clinical behavior, diagnostics and treatment.

In this 1st video of a pulmonary arterial hypertension series, Prof. dr. Galiè demonstrates the pathophysiology of PAH and its characteristics, including hemodynamics and assessment of right heart catheterization.

Which clinical PH groups can be distinguished?

Pulmonary Arterial Hypertension (PAH) - video 2

Jan. 10, 2017 - Bologna, Italy - Prof Nazzareno Galiè
Series of videos in which Prof. dr. Galiè discusses the pathophysiology and management of pulmonary arterial hypertension (PAH), including clinical behavior, diagnostics and treatment.

In this 2nd video of a pulmonary arterial hypertension series, Prof. dr. Galiè explains the various clinical PH subgroups that can be distuinguised, their pathology and relation to survival.

How common is PAH and what are its risk factors?

Pulmonary Arterial Hypertension (PAH) - video 3

Jan. 9, 2017 - Bologna, Italy - Prof Nazzareno Galiè
Series of videos in which Prof. dr. Galiè discusses the pathophysiology and management of pulmonary arterial hypertension (PAH), including clinical behavior, diagnostics and treatment.

In this 3rd video of a pulmonary arterial hypertension series, Prof. dr. Galiè shows the incidence and characteristics of the PH subgroups and its associated risk factors.

How is PAH diagnosed?

Pulmonary Arterial Hypertension (PAH) - video 4

Jan. 8, 2017 - Bologna, Italy - Prof Nazzareno Galiè
Series of videos in which Prof. dr. Galiè discusses the pathophysiology and management of pulmonary arterial hypertension (PAH), including clinical behavior, diagnostics and treatment.

In this 4th video of a pulmonary arterial hypertension series, Prof. dr. Galiè lists the symptoms and signs of PH, as well as clinical examinations, and discusses the diagnostic algorithm.

How can PAH patients be functionally classified

Pulmonary Arterial Hypertension (PAH) - video 1

Jan. 7, 2017 - Bologna, Italy - Nazzareno Galiè, MD
Series of videos in which Prof. dr. Galiè discusses the pathophysiology and management of pulmonary arterial hypertension (PAH), including clinical behavior, diagnostics and treatment.

In this 5th video of a pulmonary arterial hypertension series, Prof. dr. Galiè focusses on the behaviour of the 4 functional classes of PAH, including their relation to survival.

How is the prognosis of PAH established?

Pulmonary Arterial Hypertension (PAH) - video 6

Jan. 6, 2017 - Bologna, Italy - Nazzareno Galiè, MD
Series of videos in which Prof. dr. Galiè discusses the pathophysiology and management of pulmonary arterial hypertension (PAH), including clinical behavior, diagnostics and treatment.

In this 6th video of a pulmonary arterial hypertension series, Prof. dr. Galiè elaborates on the risk assessment table and clinical tests that should be performed for adequate diagnosis and follow-up.

Which treatment options can be pursued and which drugs are approved for PAH?

Pulmonary Arterial Hypertension (PAH) - video 7

Jan. 5, 2017 - Bologna, Italy - Prof Nazzareno Galiè
Series of videos in which Prof. dr. Galiè discusses the pathophysiology and management of pulmonary arterial hypertension (PAH), including clinical behavior, diagnostics and treatment.

In this 7th video of a pulmonary arterial hypertension series, Prof. dr. Galiè tells how to treat PAH patients according to the treatment algorithm and disusses the characteristics and evidence of the available drugs in more detail.

How do we follow-up PAH patients non-responsive to therapy and how can therapy be optimized?

Pulmonary Arterial Hypertension (PAH) - video 8

Jan. 10, 2017 - Bologna, Italy - Nazzareno Galiè, MD
Series of videos in which Prof. dr. Galiè discusses the pathophysiology and management of pulmonary arterial hypertension (PAH), including clinical behavior, diagnostics and treatment.

In this 8th video of a pulmonary arterial hypertension series, prof. dr. Galiè mentions further treatment options for non-responsive patients, including transplantation, and the organization of referral centers for most optimal care of patients.

Emerging therapies and treatment strategies in pulmonary arterial hypertension

Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Paul R. Forfia, MD - Philadelphia, PA, USA
Pulmonary arterial hypertension can be treated by targeting the prostacyclin pathway or with an endothelial receptor antagonist. Combination therapy is a novel treatment strategy.

Paul Forfia summarises the available treatment options for pulmonary arterial hypertension and the new strategy of combination therapy. Adjusting medication based on monitoring right ventricular size and function is a new and important treatment goal.